| 23.52 -0.71 (-2.93%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.97 | 1-year : | 33.83 |
| Resists | First : | 24.8 | Second : | 28.97 |
| Pivot price | 22.14  |
|||
| Supports | First : | 20.59 | Second : | 18 |
| MAs | MA(5) : | 23.6 |
MA(20) : | 21.7 |
| MA(100) : | 26.92 |
MA(250) : | 25.52 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 86.5 |
D(3) : | 91.2 |
| RSI | RSI(14): 54.8 |
|||
| 52-week | High : | 35.59 | Low : | 15.43 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RVMD ] has closed below upper band by 20.2%. Bollinger Bands are 38.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.11 - 24.24 | 24.24 - 24.35 |
| Low: | 23.06 - 23.23 | 23.23 - 23.36 |
| Close: | 23.27 - 23.52 | 23.52 - 23.73 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Fri, 17 Nov 2023
A great week that adds to Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns, institutional investors who ... - Yahoo Finance
Tue, 14 Nov 2023
Should You Hold Revolution Medicines Inc (RVMD) Stock Tuesday? - InvestorsObserver
Mon, 13 Nov 2023
Do Traders Think Revolution Medicines Inc (RVMD) Can Turn Around Monday? - InvestorsObserver
Tue, 07 Nov 2023
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript - Yahoo Finance
Mon, 06 Nov 2023
Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress - Yahoo Finance
Thu, 26 Oct 2023
Revolution Medicines Inc Shares Close the Week 31.3% Lower - Weekly Wrap - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 164 (M) |
| Held by Insiders | 1.0697e+008 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 10,870 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.641e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 409.7 % |
| Return on Equity (ttm) | -25.5 % |
| Qtrly Rev. Growth | 2.617e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -29.69 |
| EBITDA (p.s.) | -1.48088e+008 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -292 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.8 |
| Price to Cash Flow | 4.51 |
| Dividend | 0 |
| Forward Dividend | 1.625e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|